
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc. has developed the LIBERTY Endovascular Robotic System, which is anticipated to enhance procedure efficiency, lower costs, and improve overall care quality in endovascular procedures. The total addressable market for the company could grow from 2.5 million annual peripheral endovascular procedures in the U.S., contributing to an estimated market value of $843 million for the firm, supported by a discounted cash flow-based asset value of $781 million for the LIBERTY System. Additionally, the system's performance, evidenced by a remarkable 92% relative reduction in radiation exposure for operators, further underscores the technological advancement and potential for widespread adoption within the medical community.
Bears say
Microbot Medical faces significant risks that may hinder its financial performance, particularly slower than expected commercial uptake influenced by market size, penetration rates, and competition in the medical device sector. Additionally, there is a concern regarding potential dilution risk, which could affect shareholder value and investor confidence. These factors contribute to a challenging outlook for the company's stock, reflecting uncertainties in its market adoption and financial stability.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares